RespireLYFTMLive Your Fullest

Share with your buying team

Launch respiratory support.Measure the case to expand.

A practical starting brief for employers, benefits consultants and clinical sponsors. Scope and commercial terms are tailored to the organization.

How a launch is scoped

Scoped to your workforce. A clear launch. Evidence for your next decision.

01

Participants

Adults with asthma, COPD or chronic cough. The launch group—one site, one region or the whole eligible workforce—is set with you, with device requirements agreed for your organization.

02

Timing

A launch planned around your workforce: onboarding, participant support and a review date agreed before launch, so the expansion decision lands inside your planning cycle.

03

Experience

Cough and inhaler use captured for the participant, watch measurements, connected peak flow, local conditions and a respiratory food rating—one personal Breathing Fingerprint. Patterns become one small step at a time, technique coached on the wrist, and progress people can see. A compatible smartwatch adds inhaler logging and technique coaching—no smart inhaler, no clip-on sensor, nothing to ship or recover.

Patent-protected. No hardware to distribute.

What the buying team receives

A program designed around your next decision.

  • A cohort, invitation and participant-support plan.
  • Agreed activation, continued-use, experience and operational measures.
  • Defined roles, data access and privacy responsibilities.
  • Aggregate results showing participation, continued use, participant feedback—including what participants report about nights and workdays disturbed by their breathing, at the start and at the readout—and support required—with recommendations for the next phase.
  • A tailored commercial proposal covering scope, setup, support and renewal.

Employers receive agreed aggregate reporting. Individual health records are not an employer performance-monitoring tool. Claims-linked savings or clinical outcome evaluation require a separately agreed design.